Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Basic): 2009-2025

Historic EPS (Basic) for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$0.29.

  • Myriad Genetics' EPS (Basic) fell 20.83% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 238.37%. This contributed to the annual value of -$1.41 for FY2024, which is 55.66% up from last year.
  • As of Q3 2025, Myriad Genetics' EPS (Basic) stood at -$0.29, which was up 91.88% from -$3.57 recorded in Q2 2025.
  • Myriad Genetics' EPS (Basic)'s 5-year high stood at $0.31 during Q3 2021, with a 5-year trough of -$3.57 in Q2 2025.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.41 (2024), whereas its average is -$0.77.
  • Its EPS (Basic) has fluctuated over the past 5 years, first spiked by 255.00% in 2021, then tumbled by 770.73% in 2025.
  • Over the past 5 years, Myriad Genetics' EPS (Basic) (Quarterly) stood at -$0.10 in 2021, then slumped by 420.00% to -$0.52 in 2022, then skyrocketed by 34.62% to -$0.34 in 2023, then plummeted by 38.24% to -$0.47 in 2024, then dropped by 20.83% to -$0.29 in 2025.
  • Its EPS (Basic) was -$0.29 in Q3 2025, compared to -$3.57 in Q2 2025 and -$0.00 in Q1 2025.